Christie Group creates largest UK specialist pharmacy agent
Christie Group, a business services firm, has acquired specialist pharmacy business agents Orridge Business Sales for an undisclosed sum, creating the UK's largest specialist pharmacy agency and advisory practice.
Christie Group, a business services firm, has acquired specialist pharmacy business agents Orridge Business Sales for an undisclosed sum, creating the UK's largest specialist pharmacy agency and advisory practice.
The acquisition of is being made to enable the group to further exploit opportunities that exist across the client bases of both companies.
David Rugg, Chief Executive of Christie Group, said: "This acquisition is extremely exciting for us and a natural expansion of our presence in the pharmacy sector.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"In a period when the pharmacy sector continues to demonstrate its resilience to general market conditions and its popularity with investors, the bringing of Orridge Business Sales into the Christie + Co fold is very timely," he said.
The share price rose 1.98% to 51.50p.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.